ARK Genomic Revolution ETF
ARKG
261 hedge funds and large institutions have $535M invested in ARK Genomic Revolution ETF in 2024 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 54 increasing their positions, 93 reducing their positions, and 47 closing their positions.
4.42% more ownership
Funds ownership: 37.22% → 41.64% (+4.4%)
8% less funds holding
Funds holding: 284 → 261 (-23)
12% less capital invested
Capital invested by funds: $609M → $535M (-$74.2M)
38% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 47
41% less call options, than puts
Call options by funds: $98.4M | Put options by funds: $167M
42% less repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 93
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$28.4M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$15.3M |
| 3 |
Goldman Sachs
New York
|
+$14.1M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$12.1M |
| 5 |
GS
GTS Securities
New York
|
+$4.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$10.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$7.45M |
| 3 |
LC
Longitude (Cayman)
Grand Cayman,
Cayman Islands
|
-$2.5M |
| 4 |
Two Sigma Investments
New York
|
-$2.49M |
| 5 |
Citigroup
New York
|
-$1.96M |
ARKG Hedge Fund Activity: Q2 2024 in Review
261 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in ARK Genomic Revolution ETF (ARKG) for Q2 2024, worth a combined $535M — down 12% from $609M a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of ARKG and 29 opened new positions — a net loss of 18 holders — while 93 trimmed existing stakes and 54 added.
The largest buyer was JP Morgan Chase, adding an estimated $28.4M. The largest seller was Morgan Stanley, cutting an estimated $10.5M.
- 261 institutional investors held ARK Genomic Revolution ETF (ARKG) as of Q2 2024, down from 284 in Q1 2024.
- Funds reported $535M of ARK Genomic Revolution ETF stock for Q2 2024, down 12% quarter-over-quarter.
- 29 funds opened new ARK Genomic Revolution ETF positions in Q2 2024 and 47 closed out, a net change of -18 holders.
- The largest ARK Genomic Revolution ETF buyer in Q2 2024 was JP Morgan Chase, an estimated $28.4M added.
- The largest ARK Genomic Revolution ETF seller in Q2 2024 was Morgan Stanley, an estimated $10.5M sold.
Based on aggregated 13F filings for Q2 2024.